Lyra Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Lyra Therapeutics has a total shareholder equity of $89.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $142.6M and $53.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$102.75m |
| Equity | US$89.42m |
| Total liabilities | US$53.18m |
| Total assets | US$142.60m |
Recent financial health updates
Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?
Jan 25
We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully
Sep 10Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?
Mar 12Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?
Mar 30Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?
Dec 14We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth
Aug 28Recent updates
Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?
Jan 25We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully
Sep 10Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?
Mar 12Lyra Therapeutics appoints Nieman as Chief Medical Officer
Jul 05Lyra Therapeutics: Progress In The Clinic
May 18A First Look At Lyra Therapeutics
Apr 21Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?
Mar 30Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?
Dec 14We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth
Aug 28We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate
May 04How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?
Mar 05Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth
Jan 11
Lyra Therapeutics down 19% underwhelming data from lead program
Dec 07Lyra Therapeutics: An Intriguing Risk/Reward Proposition Tackling Chronic Rhinosinusitis
Nov 24Financial Position Analysis
Short Term Liabilities: LYRA's short term assets ($104.8M) exceed its short term liabilities ($19.6M).
Long Term Liabilities: LYRA's short term assets ($104.8M) exceed its long term liabilities ($33.6M).
Debt to Equity History and Analysis
Debt Level: LYRA is debt free.
Reducing Debt: LYRA has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LYRA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: LYRA has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 35% each year.